UOC
ACRS icon

UBS O'Connor’s Aclaris Therapeutics ACRS Stock Holding History

UBS O'Connor’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68,014
Closed -$466K – 507
2023
Q3 		$466K Sell
68,014
-5,000
-7% -$42.7K 0.01% 409
2023
Q2 		$757K Sell
73,014
-10,664
-13% -$96.5K 0.02% 409
2023
Q1 		$677K Buy
+83,678
New +$1.06M 0.02% 442
2022
Q4 		– Sell
-113,426
Closed -$1.78M – 16
2022
Q3 		$1.78M Hold
113,426
– – 0.02% 657
2022
Q2 		$1.58M Buy
+113,426
New +$1.59M 0.02% 700

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

UBS O'Connor's ACRS Position: Q4 2023 in Review

UBS O'Connor sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 68,014 shares — an estimated $466K sold.

UBS O'Connor first reported a position in ACRS in Q2 2022 and held it in 5 quarters. The position peaked at $1.78M in Q3 2022. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • UBS O'Connor reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 68,014 Aclaris Therapeutics shares in Q4 2023, an estimated $466K.
  • UBS O'Connor first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 5 quarters.
  • UBS O'Connor's Aclaris Therapeutics position peaked at $1.78M in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.